EP1448792A1 - Kit de diagnostic, puce adn et methodes pour etablir le diagnostic ou effectuer le controle du traitement d'un cancer du testicule - Google Patents
Kit de diagnostic, puce adn et methodes pour etablir le diagnostic ou effectuer le controle du traitement d'un cancer du testiculeInfo
- Publication number
- EP1448792A1 EP1448792A1 EP01274739A EP01274739A EP1448792A1 EP 1448792 A1 EP1448792 A1 EP 1448792A1 EP 01274739 A EP01274739 A EP 01274739A EP 01274739 A EP01274739 A EP 01274739A EP 1448792 A1 EP1448792 A1 EP 1448792A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cdna
- diagnostic kit
- cells
- oligonucleotides
- kit according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 46
- 208000024313 Testicular Neoplasms Diseases 0.000 title claims abstract description 35
- 201000003120 testicular cancer Diseases 0.000 title claims abstract description 32
- 238000003745 diagnosis Methods 0.000 title claims abstract description 10
- 206010057644 Testis cancer Diseases 0.000 title abstract description 9
- 239000008280 blood Substances 0.000 claims abstract description 32
- 210000004369 blood Anatomy 0.000 claims abstract description 31
- 239000002299 complementary DNA Substances 0.000 claims abstract description 28
- 238000001514 detection method Methods 0.000 claims abstract description 22
- 208000025189 neoplasm of testis Diseases 0.000 claims abstract description 21
- 238000003752 polymerase chain reaction Methods 0.000 claims abstract description 12
- 238000000018 DNA microarray Methods 0.000 claims abstract description 6
- 108020004999 messenger RNA Proteins 0.000 claims abstract 11
- 210000004027 cell Anatomy 0.000 claims description 56
- 210000004881 tumor cell Anatomy 0.000 claims description 29
- 108091034117 Oligonucleotide Proteins 0.000 claims description 28
- 238000009007 Diagnostic Kit Methods 0.000 claims description 26
- 108010073466 Bombesin Receptors Proteins 0.000 claims description 15
- 102000047481 Gastrin-releasing peptide receptors Human genes 0.000 claims description 15
- 108020004414 DNA Proteins 0.000 claims description 14
- 239000000439 tumor marker Substances 0.000 claims description 14
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 13
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 13
- 238000000926 separation method Methods 0.000 claims description 13
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 11
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 11
- 238000002493 microarray Methods 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 102000007469 Actins Human genes 0.000 claims description 8
- 108010085238 Actins Proteins 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 210000000601 blood cell Anatomy 0.000 claims description 7
- 230000009401 metastasis Effects 0.000 claims description 7
- 102000018802 High Mobility Group Proteins Human genes 0.000 claims description 6
- 101710176246 High mobility group protein Proteins 0.000 claims description 6
- 102000001708 Protein Isoforms Human genes 0.000 claims description 6
- 108010029485 Protein Isoforms Proteins 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 6
- 239000006249 magnetic particle Substances 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 238000012356 Product development Methods 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- 210000000265 leukocyte Anatomy 0.000 claims description 3
- 238000003753 real-time PCR Methods 0.000 claims description 3
- 230000009089 cytolysis Effects 0.000 claims description 2
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 210000005087 mononuclear cell Anatomy 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 210000002826 placenta Anatomy 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000003169 placental effect Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 108091028026 C-DNA Proteins 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 102000008217 Pregnancy Proteins Human genes 0.000 claims 1
- 108010035746 Pregnancy Proteins Proteins 0.000 claims 1
- 108010006785 Taq Polymerase Proteins 0.000 claims 1
- 241000589500 Thermus aquaticus Species 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 238000001502 gel electrophoresis Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000013641 positive control Substances 0.000 claims 1
- 108091008146 restriction endonucleases Proteins 0.000 claims 1
- 239000001226 triphosphate Substances 0.000 claims 1
- 235000011178 triphosphate Nutrition 0.000 claims 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 17
- 230000014509 gene expression Effects 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 6
- 238000010839 reverse transcription Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 102100025677 Alkaline phosphatase, germ cell type Human genes 0.000 abstract 1
- 101000574440 Homo sapiens Alkaline phosphatase, germ cell type Proteins 0.000 abstract 1
- 101001068480 Homo sapiens Guanylyl cyclase-activating protein 1 Proteins 0.000 abstract 1
- BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 6
- 238000000137 annealing Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000049982 HMGA2 Human genes 0.000 description 4
- 108700039143 HMGA2 Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 238000007403 mPCR Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000018732 detection of tumor cell Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007885 magnetic separation Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003918 blood extract Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000010225 mixed cell type cancer Diseases 0.000 description 1
- 208000029638 mixed neoplasm Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000011518 platinum-based chemotherapy Methods 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
Definitions
- the present invention relates to a diagnostic kit, a DNA chip and a method for diagnosis or treatment control for testicular cancer.
- I - In the context of cancer prevention and follow-up care, it is very important to be able to detect malignant testicular tumors or recurrent malignant testicular tumors early on using the appearance of metastatic tumor lines in the blood.
- Testicular cancer is responsible for less than 2% of all malignant tumors in men. However, 20-30% of all cancers among men aged 40 are testicular cancer. The number of new cases each year in the Federal Republic of Germany, for example, is approximately 3600, with approximately 240 men dying from testicular cancer. The highest incidence is found between the ages of 25 and 40. By progress in oncology see therapy, over 90% of all those affected can be cured in the long term. The high survival rates are due to the pronounced effectiveness of cis-platinum-based chemotherapy.
- tumor markers at the protein level are determined quantitatively in the blood or in other body fluids in cancer patients.
- these detection methods are only of limited suitability for tumor diagnosis or treatment control / aftercare in testicular tumors, since increased tumor marker values in body fluids are also caused by non-tumor diseases, such as inflammation of the gastrointestinal tract, cirrhosis of the liver, viral infections or heavy smoking • can .
- EP 0 520 794 B1 discloses such a method in which metastases in body tissues or liquids are detected. In doing so, nucleic acids are detected, for example by means of amplification by polymerase chain reaction. The method is now crucially based on the fact that the detected nucleic acid sequence is expressed in cells of the tissue of origin of a tumor, ie in tumor cells and, depending on the markec, also in the healthy cells of the tissue of origin. Another condition is that this sequence is not expressed in those cells whose tissue is being examined.
- this method is ultimately based on the detection of cells that should not occur in the blood sample of ⁇ healthy individuals.
- the object of the present invention is therefore to provide a method, a diagnostic kit and a nucleic acid microarray with which tumor cells in testicular tumor diseases in peripheral blood can be detected.
- This object is achieved by the diagnostic kit according to claim 1, the microarray according to claim 20 and the method according to claim 22 and their use according to claim 45.
- Advantageous further developments of the diagnostic kit, microarrays, method or uses according to the invention are given in the respective dependent claims.
- the present invention is essentially based on the fact that testicular tumor markers are not detected in the blood of patients at an immunological or enzymatic level, but that the mRNA (messenger ribonucleic acid) of testicular tumor markers is detected in a blood sample, the tumor markers being associated with a tumor Represent gene expression.
- the placenta-specific alkaline phosphatase (PLAP) and the germline-specific alkaline phosphatase (GCAP), which are expressed in testicular tumors, the epithelial glycoprotein (GA733__2 or EGP40), the high-mobility group protein isoform IC (HMGI-C) and the gastrin releasing peptide receptor (GRPR) are detected.
- the detection can be carried out for only one of the markers or for any number of these four testicular tumor markers in combination with one another, but at least the mRNA of the markers GA733.2 and / or GCAP / PLAP is detected.
- the kit according to the invention can therefore Contain oligonucleotide pairs for only one or any selection or all of the four testicular tumor markers.
- testicular tumor markers are also expressed in the original tissue and as a protein in the bloodstream. long.
- only cells are detected that are on the one hand in the blood sample and on the other hand express the respective testicular tumor marker. Consequently, these are tumor cells that originate from their original testicular tumor tissue and have been carried over into the patient's blood. Since the mRNA of the markers examined is not expressed in the blood of a testicular tumor patient, there is a direct correlation between the occurrence of the associated mRNA and metastasis even in the early stage of the metastasis process.
- testicular tumor marker not only is the mRNA of an individual testicular tumor marker detected, but a combination of markers is examined.
- This makes it possible, for example, to detect all types of testicular cancer via their cells metastasizing in the blood.
- seminous and non-seminous testicular cancer forms or mixed tumors with a semino fraction and thus 90-95% of all malignant tumors of the testis, namely all germ cell tumors, are detected.
- tumor cells can also be recognized when the expression of a particular marker in a patient or in a disease stage is relatively low, which could otherwise lead to a supposedly negative result.
- additional markers mostly comes up against limits because mononuclear blood cells express background expression
- the specificity is a critical point due to the very high amplification rate.
- the slightest contamination, such as from foreign RNA or atypical transcription, can falsify the result.
- RNA isolated as a detection basis and the cDNA synthesized from it Central to the quality of the RNA isolated as a detection basis and the cDNA synthesized from it is the enrichment of the cell fraction used for this from the blood sample used. Various methods are available for this:
- tumor cell detection rate from 1 tumor cell to 10 7 mononuclear blood cells.
- the tumor cells are separated from mononuclear blood cells by means of specific antibodies or an antibody mixture.
- the separation can be carried out by means of magnetic particles (Dynal) to which the antibodies are bound. This is described in more detail below.
- Eukaryotic cells have a large number of different molecules on their cell surface.
- the combination of the expressed surface molecules differs according to the origin and the function of the individual cell, so that cell-type-specific patterns arise.
- For ' detection antibodies are used in this cell type-specific pattern.
- Antibodies bind to their antigen with high specificity, here to selected surface molecules. This property is used to recognize and differentiate cells by means of specific antibody binding based on their cell type-specific patterns.
- tumor cells of this cell type Since this special pattern of surface antigens in tumor cells also differs from the typical blood cell patterns, tumor cells can be differentiated in the blood. To identify tumor cells, antibodies that specifically recognize these special surface proteins are used as tools. The specific antibody binding is used for different analysis and separation methods.
- Antibodies are coupled with fluorescent dyes for flow cytometric analysis. Scattered cells become constant
- Laser light source
- the fluorescent dyes bound to the antibodies are excited and emit light of specific wavelengths.
- the emitted light is detected and the measured one
- Digitized signal stored The light signal can be assigned to individual cells.
- the antibody-labeled cell is thus recognized and can now be separated from other cells. For separation, the cells are made in the smallest
- Such an enrichment can be done, for example, by FACS flow cytometry.
- the mononuclear cells from the fraction enriched under b) are incubated with fluorescence-labeled mononuclear antibodies against tumor-specific surface proteins.
- the labeled cells are washed twice with PBS and then 10 7 cells are resuspended in 1 ml PBS.
- a FACS Vantage SE flow cytometer (Becton Dickinson) is used to isolate the tumor cells.
- the CellQuest program is used for data acquisition, instrument control and data evaluation.
- the sorted cells are transferred to a 1.5 l reaction vessel (filled with 1 ml PBS).
- the RNA can then be isolated as described later.
- antibodies are consequently covalently coupled to pseudomagnetic particles that have a defined number of chemically activated sites on their surface.
- the specificity of the separation is determined via the specificity of the antibodies.
- a blood sample containing tumor cells is mixed with antibody-coupled magnetic particles; then particles and blood are moved relative to each other, for example by “over-
- tumor cells are detected in general, but with high specificity. This is due to the selective expression of certain surface proteins that differentiate cancer cells from other cells.
- Antibody mixtures of this type show an increased sensitivity in comparison to the separately used antibodies in cell recognition and cell separation, regardless of the method used.
- a blood sample is taken from a patient.
- RNS processing from a milliliter of this whole blood is carried out using the QIAampRNA-Blood Mini Kit TM (from Qiagen, Hilden). Contamination with genomic DNA is avoided by an additional DNA digestion with the RNase-Free DNase Set TM (company Qiagen, Hilden) on the column.
- RNA isolation As an alternative to the RNA isolation described above, it is also possible to take up the isolated fraction of mononuclear blood cells, as described above, in TRIzol reagent from Gibco BRL, NY, USA, to lyse them and to homogenize them using a pipette. The RNA-containing aqueous phase is then precipitated from a chloroform extraction in isopropanol at -80 ° C. After washing twice in 80% ethanol, the pellet is air-dried and then resuspended in RNase-free water.
- RNA was then denatured in an appropriate volume of water together with oligo (dT) ⁇ 5 primers from Promega, Mannheim for 5 minutes at 65 ° C. and then incubated directly on ice. This was followed by cDNA synthesis at 37 ° C for one hour and a subsequent inactivation of the added reverse transcriptase for 5 minutes at 93 ° C and Cooling down on ice.
- the entire reverse transcription was carried out using the Sensiscript TM reverse transcriptase kit from Qiagen, Hilden.
- the PCR synthesis was carried out in a 20 ⁇ l reaction mixture
- the multiplex PCR was carried out under the conditions given in Table 5 and at the marker-specific annealing temperatures and number of cycles given in Table 6.
- the annealing temperature is indicated by x, whereby the corresponding annealing temperature from table 6 was used in each case.
- Lane 1 shows the result of a detection by means of electrophoresis using a DNA 500 chip (Agilent) and an Agilent Bioanalyzer 2100.
- Lane 1 shows a 100 bp ladder
- lane 2 shows a cDNA control without RNA in the approach
- lane 3 one PCR control without cDNA in the approach
- lane 4 a negative control for GCAP / PLAP with RNA from a healthy control person in the approach
- lane 5 the sample from a diseased person.
- control measurement of ⁇ -actin is only positive in the two real blood samples of lanes 4 and 5, while only lane 5 has the expected band for GCAP / PLAP as testicular tumor marker.
- FIG. 2 Another result is shown in FIG. 2.
- the detection was also carried out using an Agilent Bioanalyzer 2100 and a DNA 500 assay chip from Agilent.
- Lanes 1 to 6 show a multiplex PCR of the cDNA from GCAP and GA733.2 and lanes 7 to 13 show a multiplex PCR of the cDNA from GCAP, GA733.2, GRPR and HMGI-C.
- the designations cDNA- Control, PCR control and negative control refer to samples without RNA, without cDNA or with RNA from a healthy control person. It can be seen in lanes 5, 9 and 13, respectively, that only the testicular tumor samples in the detection of the cDNA and therefore the mRNA are positive for GCAP / PLAP, GA733.2, GRPR and HMGI-C.
- agarose gel electrophoresis can of course also be used, in which, for example, 25 ⁇ l of the PCR product shown above are separated using a 2.5% agarose gel and the DNA bands are subsequently stained and visible with ethidium bromide be made.
- the documentation can be carried out, for example, using the Inta DUO Store System.
- a fragment analysis using the ABI Prism 310 Genetic Analyzer can also be used for evaluation.
- a PCR with fluorescence-labeled primers is carried out and then, for example, 1 ⁇ l of the respective PCR product is used in a dilution of 1:50.
- tumor marker detection can also be carried out using real-time PCR using DANN-intercalating fluorescent dyes (eg LightCycler TM and CybrGreen TM from Hoffmann-Röche). For this purpose, for example, quantification is carried out using fluorescence-based real-time PCR.
- DANN-intercalating fluorescent dyes eg LightCycler TM and CybrGreen TM from Hoffmann-Röche.
- quantification is carried out using fluorescence-based real-time PCR.
- a sequence-specific fluorescence-labeled hybridization sample is added to the PCR approach, by means of which the product development, ie the amplification, can be followed after each cycle of the PCR by means of the fluorescence emitted by it.
- Special standards can then be used to draw conclusions about the quantities of starting RNA.
- This also makes it possible to quantify the testicular tumor-associated RNA present in the blood sample and, consequently, to make a direct statement about the response to a selected therapy method.
- This method can be carried out, for example, with a Light-Cycler TM from Röche, Basel or a Taq-Man TM from PE Applied Bio-Systems, Wieterstadt, as is already well known from the literature.
- the device according to the invention and the method according to the invention also make it possible to continue using the sorted and separated cells as described above as desired.
- these can be inserted into a suitable cell culture medium and cultivated in situ.
- the sorted cells are carrier applied. Additional surface markers can be detected chytochemically or using fluorescence microscopy. Genetic analyzes can also be carried out, such as chromosome analyzes using FISH (fluorescence in situ hybridization) or karyogram generation.
- FISH fluorescence in situ hybridization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2001/013606 WO2003044224A1 (fr) | 2001-11-22 | 2001-11-22 | Kit de diagnostic, puce adn et methodes pour etablir le diagnostic ou effectuer le controle du traitement d'un cancer du testicule |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1448792A1 true EP1448792A1 (fr) | 2004-08-25 |
Family
ID=8164690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01274739A Withdrawn EP1448792A1 (fr) | 2001-11-22 | 2001-11-22 | Kit de diagnostic, puce adn et methodes pour etablir le diagnostic ou effectuer le controle du traitement d'un cancer du testicule |
Country Status (4)
Country | Link |
---|---|
US (1) | US20050118591A1 (fr) |
EP (1) | EP1448792A1 (fr) |
AU (1) | AU2002219137A1 (fr) |
WO (1) | WO2003044224A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4336198B2 (ja) | 2001-09-06 | 2009-09-30 | アトナーゲン アクチエンゲゼルシャフト | 細胞の選択、および/または定性および/または定量検出のための方法および診断キット |
WO2003070935A1 (fr) * | 2002-02-20 | 2003-08-28 | Sysmex Corporation | Amorces pour l'amplification d'acides nucleiques servant a la detection de l'arnm d'un gene domestique et methode d'essai faisant intervenir ces amorces |
EP2359689B1 (fr) | 2002-09-27 | 2015-08-26 | The General Hospital Corporation | Dispositif microfluidique pour la séparation de cellules et usage du dispositif |
JP2007533305A (ja) * | 2004-03-03 | 2007-11-22 | ザ ジェネラル ホスピタル コーポレーション | 微小流動環境において細胞および生体分子を単離するための磁気装置 |
US20070196820A1 (en) | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
GB2427468B (en) * | 2005-04-05 | 2011-03-02 | Cellpoint Diagnostics | Cell separation device and method for the detection of EpCAM positive cells |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070059716A1 (en) * | 2005-09-15 | 2007-03-15 | Ulysses Balis | Methods for detecting fetal abnormality |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
EP2589668A1 (fr) | 2006-06-14 | 2013-05-08 | Verinata Health, Inc | Analyse de cellules rares utilisant la division d'échantillons et les marqueurs d'ADN |
US20080070792A1 (en) | 2006-06-14 | 2008-03-20 | Roland Stoughton | Use of highly parallel snp genotyping for fetal diagnosis |
CA3069082C (fr) | 2008-09-20 | 2022-03-22 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic non effractif d'aneuploidie foetale par sequencage |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05500512A (ja) * | 1989-09-14 | 1993-02-04 | バクスター インターナショナル インコーポレーテッド | 薬学的組成物を製造するための方法および装置 |
AU662906B2 (en) * | 1991-06-26 | 1995-09-21 | F. Hoffmann-La Roche Ag | Methods for detection of carcinoma metastases by nucleic acid amplification |
US6165467A (en) * | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
ATE172890T1 (de) * | 1995-02-21 | 1998-11-15 | Iqbal W Dr Siddiqi | Apparat und verfahren zum mischen und trennen durch verwendung von magnetischen teilchen |
GB9518156D0 (en) * | 1995-09-06 | 1995-11-08 | Medical Res Council | Method of isolating cells |
-
2001
- 2001-11-22 AU AU2002219137A patent/AU2002219137A1/en not_active Abandoned
- 2001-11-22 US US10/496,410 patent/US20050118591A1/en not_active Abandoned
- 2001-11-22 WO PCT/EP2001/013606 patent/WO2003044224A1/fr not_active Application Discontinuation
- 2001-11-22 EP EP01274739A patent/EP1448792A1/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO03044224A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002219137A1 (en) | 2003-06-10 |
WO2003044224A1 (fr) | 2003-05-30 |
US20050118591A1 (en) | 2005-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10143776A1 (de) | Verfahren und Kit zur Diagnostik oder Behandlungskontrolle von Brustkrebs | |
EP1409727B1 (fr) | Procede destines a la detection qualitative et/ou quantitative de cellules | |
DE60029092T2 (de) | Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen | |
US20100112586A1 (en) | Diagnosis of fetal abnormalities by comparative genomic hybridization analysis | |
EP1448792A1 (fr) | Kit de diagnostic, puce adn et methodes pour etablir le diagnostic ou effectuer le controle du traitement d'un cancer du testicule | |
US20210318310A1 (en) | Methods for monitoring polymorphonuclear myeloid derived suppressor cells | |
JP2012244989A (ja) | リアルタイム重合反応を用いた癌診断のための情報提供方法及びこのための癌診断用キット | |
EP1409745B1 (fr) | Procede et necessaire destines au diagnostic ou au controle du traitement du cancer de l'intestin | |
WO2003023060A2 (fr) | Methode et trousse de diagnostic ou de surveillance du traitement du cancer du sein | |
CN110806480B (zh) | 肿瘤特异性细胞亚群和特征基因及其应用 | |
JP2024023284A (ja) | がんのスクリーニング、診断、治療、及び再発における巨細胞の核酸の特徴付けの使用方法 | |
EP1529206B1 (fr) | Procede de detection immunocytologique ou moleculaire de cellules tumorales disseminees dans un liquide corporel et kit associe | |
DE69725297T2 (de) | Immuno-magnetische zelltrennung zur erkennung von krebsmetastasenbildung-assozierten genen | |
CN110747275B (zh) | 肿瘤细胞标记分子及其应用 | |
CN102220432A (zh) | 西红花干品的dna指纹图谱鉴定方法及其应用 | |
DE10143775A1 (de) | Verfahren und Kit zur Diagnostik oder Behandlungskontrolle von Darmkrebs | |
EP2088204A1 (fr) | Procédé et kit pour diagnostiquer ou contrôler le traitement du cancer ovarien | |
DE10057894A1 (de) | Diagnose-Kit, DNS-Chip sowie Verfahren zur Diagnostik oder Behandlungskontrolle bei Hodenkrebs | |
DE10059776A1 (de) | Trisomie 21-Diagnostik-Kit | |
DE10102687A1 (de) | Trisomie 13-Diagnostik-Kit | |
Shi et al. | A Microfluidic Chip for Circulating Tumor Cells RNA Sequencing at Single Cell Level | |
WO2007028380A1 (fr) | Dosage immunologique in vitro fonctionnel | |
Maiese et al. | Detection of low levels of B-cell lymphoproliferative disorders | |
WO1999001573A2 (fr) | Procede et trousse d'analyse permettant de detecter les tumeurs malignes | |
EP3111220B1 (fr) | Procédures pour diagnostics moléculaires pour enrichir un acide nucléique d'un échantillon biologique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040219 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ZIEGLSCHMID, VEIT Inventor name: WASCHUETZA, STEFANIE Inventor name: STEFFENS, PIA Inventor name: KREHAN, ALF-ANDREAS Inventor name: TAMAK, CENGIZ |
|
17Q | First examination report despatched |
Effective date: 20050309 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050920 |